A 52-year-old Indian woman with obesity and type 2 diabetes presents with postmenopausal bleeding. Endometrial cancer is suspected. Which clinical or pathological feature best distinguishes early-stage Type I endometrial cancer (favorable prognosis) from early-stage Type II endometrial cancer (poor prognosis)?

## Prognostic Discrimination Between Type I and Type II Endometrial Cancer at Early Stage ### Clinical Context **Key Point:** Type I (endometrioid) and Type II (serous/clear cell) endometrial cancers have fundamentally different natural histories. Even when both are diagnosed at early stage (Stage IA–IB), Type II has significantly worse prognosis due to inherent biological aggressiveness. ### Histological Grade as the Discriminator **High-Yield:** Type I endometrial cancers are typically **low-grade (G1–G2)** at presentation and arise from a precursor of endometrial hyperplasia. Type II cancers are inherently **high-grade (G3)** and do not have a hyperplasia precursor; they arise de novo from atypical endometrial intraepithelial carcinoma (AEIC). ### Comparison of Prognostic Features | Feature | Type I (Early-Stage, Good Prognosis) | Type II (Early-Stage, Poor Prognosis) | | --- | --- | --- | | **Grade** | G1–G2 (low-grade) | G3 (high-grade) | | **Precursor** | Endometrial hyperplasia (hyperplasia → cancer sequence) | AEIC (no hyperplasia phase) | | **Myometrial Invasion** | Often superficial (<50%) | Often deep (>50%), even at early stage | | **LVSI** | Less frequent | Frequent | | **5-Year Survival (Stage IA)** | ~95% | ~50–60% | | **Recurrence Rate** | Low (5–10%) | High (30–40%) | | **Molecular Profile** | PTEN, KRAS, PIK3CA mutations; MSI | TP53 mutations; p53 overexpression | ### Why Option 1 (Grade 1–2 Histology) is Correct **Clinical Pearl:** Grade is the single most powerful prognostic discriminator between Type I and Type II endometrial cancers at early stage. A Stage IA tumor that is Grade 1–2 endometrioid (Type I) has excellent prognosis and may be managed with hysterectomy alone, whereas a Stage IA serous or clear cell (Type II) tumor, despite being early-stage, requires adjuvant chemotherapy due to high recurrence risk. **Mnemonic:** **GRADE GUIDES THERAPY** — In endometrial cancer, histological grade (and type) determines whether early-stage disease needs adjuvant treatment, not stage alone. ### Treatment Implications 1. **Type I, Grade 1–2, Stage IA:** Surgery alone (hysterectomy + bilateral salpingo-oophorectomy); no adjuvant therapy if no other risk factors. 2. **Type II (any stage ≤II):** Adjuvant chemotherapy (carboplatin + paclitaxel) regardless of stage, due to inherent aggressive biology. ### Why Other Options Are Incorrect - **Endometrial hyperplasia as precursor** (Option 0): While Type I arises from hyperplasia and Type II does not, this is a historical/molecular feature, not a discriminator visible on a single biopsy of established cancer. - **Absence of lymph node metastases** (Option 2): Both Type I and Type II can present without nodal involvement; this is not discriminatory. - **Myometrial invasion <50%** (Option 3): While Type I more often shows superficial invasion, Type II can also present with <50% invasion; depth alone does not reliably distinguish the two types.